Abstract-Tranilast, which is an antiallergic drug, has a potent effect on preventing postangioplasty restenosis. To elucidate this mechanism, we studied the effect of tranilast on the proliferation of vascular smooth muscle cells (SMCs) in vitro and in vivo. Tranilast decreased the growth rate of SMCs stimulated by either 10% FBS or platelet-derived growth factor. The IC 50 value, evaluated as cell number, was 100 mol/L. These inhibitory effects were associated with inhibition of the retinoblastoma gene product (pRb) phosphorylation. Because pRb phosphorylation is regulated by cyclin-dependent kinases (CDK), we investigated CDK2 and CDK4 activities and the expression of CDK inhibitor p21 waf1/cip1/sdi1 (p21). When SMCs were stimulated by 10% FBS or platelet-derived growth factor, CDK2 and CDK4 activities reached a maximum near the G 1 /S transition. Tranilast suppressed their activities by Ͼ80% without reduction of CDK2/cyclin E and CDK4/cyclin D1 protein levels. These inhibitory effects were associated with enhanced expression of p21 and elevated complexing of p21 with CDK2/CDK4. Next, rat balloon-injured carotid artery was analyzed for intimal thickening and p21 expression. Tranilast-treated rats had a 70% (PϽ0.001) smaller neointima/ media area ratio at 14 days after balloon injury compared with the controls. Immunohistochemical staining demonstrated that, in tranilast-treated rats, p21 was already present in the neointima at day 7 and strongly expressed throughout the neointima at day 14. In control rats, p21 was not observed in the neointima at day 7 but was sparsely expressed at day 14. These data demonstrate that inhibition of CDK2/CDK4 activities by the increased expression of p21 may be one mechanism by which tranilast inhibits SMC proliferation and prevents postangioplasty restenosis. (Circ Res. 1999;84:543-550.)
P roliferation and migration of vascular smooth muscle cells (SMCs) play a pivotal role in the development of restenosis and in the progression of atherosclerosis. 1 Arterial injury results in the migration of SMCs into the intimal layer of the arterial wall, where they proliferate and synthesize extracellular matrix components. Many growth factors induce the proliferation of vascular SMCs in vitro and in vivo. Among them, platelet-derived growth factor (PDGF) and basic fibroblast growth factor are important regulators of SMC behavior through their well-defined actions as potent chemoattractants and strong mitogens. Administration of these growth factors enhances intimal thickening after angioplasty in the rat, whereas injection of antibodies or use of antisense technology to block signal transduction by either of these growth factors potently inhibits postinjury intimal hyperplasia in the rat and restenosis in the pig, suggesting that SMC growth plays an important role in these pathogenesis.
Progression through the mammalian mitotic cycle is controlled by multiple holoenzymes comprising a catalytic cyclin-dependent kinase (CDK) and a cyclin regulatory subunit. Functional CDK/cyclin holoenzymes are presumed to phosphorylate target protein substrates that facilitate cell cycle progression. [2] [3] [4] Different CDK/cyclin complexes are activated in order at specific phases of the cell cycle. Progression through the first gap phase (G 1 ) requires both cyclin D-dependent CDK4/CDK6 and CDK2/cyclin E holoenzymes. 5 Functional CDK2/cyclin A and p34 cdc2 kinase (CDC2)/cyclin B pairs are assembled and activated during the second gap (G 2 ) and mitosis (M) phases, respectively. Recent evidence has suggested that CDK2 is required for entry into mitosis as a positive regulator of CDC2/cyclin B kinase activity. 6 Moreover, cyclin D/CDK complexes can phosphorylate the retinoblastoma gene product (pRb) in vitro, which suggests that these complexes may directly regulate the phosphorylation of pRb in response to growth factor stimulation. 7 The kinase activity of these cyclins/CDK complexes can be negatively regulated by CDK-inhibitory proteins, including p16
INK (p16), p21 waf1/cip1/sdi1 (p21), and p27 kip1 (p27). 8, 9 It has become apparent that p21 is a universal inhibitor of cyclin/CDK catalytic activity. 10 -12 Several lines of evidence suggest that p21 expression is regulated by the p53 tumor-suppressor protein.
The p21 gene has a p53 transcriptional regulatory motif, and cells lacking p53 express very low levels of p21. These findings have led to a model in which p21 serves as an effector of cell cycle arrest in response to activation of the p53 checkpoint pathway. However, p21 is also upregulated through p53-independent mechanisms as in the following situations: normal tissue development, cell differentiation, serum stimulation, and treatment with transforming growth factor-␤ and prostaglandin A 2 . [13] [14] [15] Although p21 monomers can associate with active cyclin D/CDK complexes in proliferating fibroblasts, 16 overexpression of p21 has been shown to inhibit the kinase activities of these cyclin/CDK complexes and to arrest the cells in the G1 phase of the cell cycle. 17 Therefore, p21 may inhibit cell cycle progression by inhibiting the cyclin/CDK-dependent phosphorylation of pRb. Tranilast, N-(3Ј,4Ј-dimethoxycinnamoyl)anthranilic acid, is generally used as an antiallergic drug. This effect is thought to result from an inhibition of the release of chemical mediators from mast cells and basophils. 18 Recently, it has been reported that tranilast markedly inhibits the proliferation and migration of SMCs as well as collagen synthesis by these cells. 19, 20 Furthermore, a double-blind, large-scale, multicenter trial demonstrated the potent preventive effect of tranilast on restenosis (restenosis rate 14.7% [tranilast 600 mg/day for 3 months, nϭ68] versus 46.5%, placebo, nϭ71; [PϽ0.001]) after percutaneous transluminal coronary angioplasty. 21 Tranilast antagonizes angiotensin II, 22 restores cytokine-induced NO production against PDGF, 23 and inhibits calcium entry in SMC. 24 Moreover, tranilast suppresses intimal hyperplasia after photochemically induced endothelial injury in the rat. 25 However, the precise mechanisms by which this drug inhibits SMC growth remains obscure. The purpose of the present study was to determine the effect of tranilast on PDGF-and FBS-induced SMC growth, the mechanism of this effect, and intimal hyperplasia after balloon injury of the rat carotid artery.
Materials and Methods
Tranilast was obtained from Kissei Pharmaceutical Co Ltd and was dissolved in DMSO; recombinant human PDGF-BB; and insulin, transferrin, and selenium (ITS Premix) from Collaborative Biomedical Products. [␥-
32 P]ATP (4500 Ci/mmol) was obtained from ICN Biochemical. The concentration of protein in cell culture was determined using the Bradford microassay procedure using a reagent from Bio-Rad. The following antibodies were used in the present study. Anti-cyclin D1 (monoclonal, 72-13G), anti-cyclin E (rabbit polyclonal, M20), anti-CDK2 (rabbit polyclonal, M-2), anti-CDK4 (rabbit polyclonal, C-22), anti-p21 (rabbit polyclonal, C-19), and anti-pRb (rabbit polyclonal, C-15) antibodies were purchased from Santa Cruz Biotechnology. Anti-human p21 mixed mouse monoclonal IgGs were obtained from Upstate Biotechnology Inc. Anti-pRb (monoclonal, G-3-245) was from Pharmingen. Anti-p53 antibodies (monoclonal, Ab-1, and sheep polyclonal, Ab-7) from Calbiochem. Rabbit nonimmune IgG was purchased from DAKO. Rabbit antimouse IgG antibody from Jackson ImmunoResearch Laboratories, Inc, was coupled to protein A-Sepharose when monoclonal antibody was used for immunoprecipitation. Histone H 1 was from Life Technologies, Inc. All other chemicals and reagents were obtained from either Wako Pure Chemical Industries or Sigma.
Cell Culture
DMEM and trypsin were obtained from Life Technologies, Inc, and FBS and penicillin-streptomycin mixture from BioWhittaker. SMCs were isolated from rat thoracic aorta by enzymatic dissociation as described by Gunther et al. 26 Cells were grown in DMEM supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin, and 100 g/mL streptomycin. They were passaged twice weekly by harvesting with trypsin/EDTA and seeding at a 1:5 ratio in flasks with a volume of 75 cm 2 (Corning). Cells grown between passages 8 and 15 were used for experiments.
Quantification of Cell Number
Cell number was measured using the crystal violet staining method described before. 27 Briefly, SMCs were suspended in DMEM containing 0.5% FBS and seeded into each well of a 96-well plate (Falcon, Becton Dickinson) at a density of 4ϫ10 3 /well. After cell attachment, the medium was replaced with DMEM containing either 10% FBS or 2% FBS, 10 ng/mL of PDGF, and ITS Premix in the presence or absence of known concentrations of tranilast. After 3 days of incubation, the cells were fixed with 10 L of 10% glutaraldehyde, stained with 0.1% crystal violet solution at pH 6.0, and dissolved with 10% acetic acid. The wells were read at 590 nm in a microplate reader (model 3550; Bio-Rad). A calibration curve was drawn on the basis of a known number of cells.
Immunological Analysis (Western Immunoblot and Immunoprecipitation)
Cell lysates were prepared with ice-cold lysis buffer containing (in mmol/L) Tris-HCl (pH 7.4) 50, NaCl 250, EDTA 5, NaF 10, DTT 0.1, phenylmethylsulfonyl fluoride 1, and leupeptin 0.1; 0.1% NP-40; and 10 g/mL aprotinin. Immunoprecipitation was performed by incubating the cell lysates obtained from one 60-mm dish with 1 g of specific antibodies against pRb, p21, p53, cyclins, and CDKs. To precipitate immune complexes, protein A-Sepharose (30 L of 50% slurry) was added and gently rotated for 1 hour at 4°C. Immunoprecipitates were washed 4 times with lysis buffer and incubated with 30 L of SDS-PAGE sample buffer for 5 minutes at 100°C. Samples were briefly spun down, and the protein in the supernatants was electrophoresed on polyacrylamide gel and transferred to a PVDF membrane (Bio-Rad Laboratories). Membranes were blocked with 5% nonfat dry milk in PBS containing 0.1% Tween-20, and immunoblotting was performed with antibodies at 1 g/mL. Positive antibody reactions were visualized using peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG (Cappel Research Products). The peroxidase reaction was developed using an enhanced chemiluminescence detection system (ECL, Amersham Corp).
Immune Complex Kinase Assays
Cell lysates were prepared with ice-cold lysis buffer (containing, in mmol/L, HEPES [pH 7.5] 50, NaCl 150, EDTA 1, EGTA 2.5, DTT 1, ␤-glycerophosphate 10, NaF 1, Na 3 VO 4 0.1, and phenylmethylsulfonyl fluoride 0.1 and 10% glycerol, 0.1% Tween-20, 10 g/mL of leupeptin, and 2 g/mL of aprotinin) and sonicated at 4°C (Micro ultrasonic cell disrupter [from KONTES], 30% power, 2 times for 10 seconds each time). Lysates were clarified by centrifugation at 10 000g for 5 minutes, and the supernatants were precipitated for 2 hours at 4°C with protein A-Sepharose beads precoated with saturating amounts of indicated antibodies. When monoclonal antibodies were used, protein A-Sepharose was pretreated with rabbit anti-mouse immunoglobulin G (Jackson ImmunoResearch Laboratories). Immunoprecipitated proteins on beads were washed 4 times with 1 mL of lysis buffer and twice in a kinase buffer (containing, in mmol/L, HEPES 50, MgCl 2 
Balloon Injury and Morphometric Analysis of Intimal Thickening
All experiments were performed in accordance with a protocol approved by the Guidelines for Animal Experimentation at Kobe University School of Medicine. Male Sprague-Dawley rats weighing 200 to 250 g were divided into 2 groups (nϭ8 per group) and fed with powdered chow. One group received 10 g of tranilast/kg chow supplement, whereas the diet of the other group was unchanged (control). After 3 days, all animals received balloon injury to the left main carotid artery. After anesthetization with sodium pentobarbital (50 mg/kg body weight IP; Abbott Laboratories), the right iliac artery was exposed through a midline incision, a 2F embelectomy catheter (Baxter Edwards Healthcare Corp) was introduced into the left common carotid artery, and the balloon was inflated with saline and drawn toward the arteriotomy site 5 times to produce a distending and de-endothelializing injury. 28 The right uninjured carotid artery was used as control tissue. At the indicated days after injury, rats were euthanized with sodium pentobarbital (intraperitoneal injection, 100 mg/kg body weight) and then perfused with saline followed by 10% formalin at physiological pressure. For immunohistochemistry and morphometric analysis, the arteries were fixed in 100% methanol overnight, and then the middle one third of the common carotid artery was cut into 4 segments and embedded in paraffin. The specimens were cross-sectioned at a thickness of 3 m and stained with hematoxylin and eosin. For immunohistochemical staining, sections were deparaffinized and rehydrated with PBS. Primary p21 antibody (Santa Cruz Biotechnology) was diluted 1:500 and incubated for 20 minutes at 37°C. Staining was performed using a labeled streptavidin biotin kit according to the recommendations of the manufacturer (DAKO Corp). Sections were counterstained with hematoxylin. Intimal and medial cross-sectional areas of 4 cross sections of the artery obtained from each rat were measured. The intima/media cross-sectional area ratios were determined using a computerized apparatus and NIH Image software (version 1.57).
Statistics
The data were analyzed using either the Student t test or 1-way ANOVA followed by the Fisher test.
Results

Effect of Tranilast on Proliferation of Rat SMCs
We first investigated the effect of tranilast on SMC proliferation in the presence of 10% FBS. Tranilast inhibited FBSinduced SMC proliferation in a dose-dependent manner. The IC 50 value, evaluated as cell number, was 100 mol/L, and complete inhibition was observed at 300 mol/L (data not shown). We then examined the effect of tranilast on the early signal-transduction pathway by PDGF-BB stimulation using the following parameters: active GTP-bound p21 ras ratios and p42 mapk , p44 mapk , phosphatidylinositol 3-kinase, and p70 S6 kinase activities. However, all of these early signaltransduction pathways were not significantly affected by tranilast treatment (data not shown).
Effect of Tranilast on PDGF-and FBS-Induced Phosphorylation of pRb
Next, we examined the effects of tranilast on the phosphorylation status of pRb in SMCs. Since the mobility shift of pRb to phosphorylated form began at 16 hours after stimulation and was sustained until 24 hours (data not shown), we examined the effect of tranilast on pRb phosphorylation at 18 hours after stimulation. Tranilast (300 mol/L) markedly inhibited the phosphorylation of pRb by stimulation with both 10% FBS and PDGF (Figure 1 ), suggesting that tranilast blocked a G 1 event that preceded pRb phosphorylation.
Effect of Tranilast on FBS-and PDGF-Induced Activation of CDK2 and CDK4 Activity
To elucidate the mechanism by which tranilast inhibits pRb phosphorylation, we measured the activities of CDK2 and CDK4, because pRb is the putative substrate for CDK2 and CDK4, which are activated during G 1 phase. We measured the activities of CDK2 and CDK4 stimulated by PDGF, 2% FBS, and ITS ( Figure 2A ). The CDK2 and CDK4 activities were low in the G 0 and early G 1 phases. They began to increase at 12 hours after stimulation, continued to increase until 24 hours, and declined at 30 hours. Tranilast (200 mol/L) added 1 hour before PDGF stimulation suppressed the activities of both CDK2 and CDK4 measured at 18 and 24 hours. At 18 hours, tranilast (200 mol/L) suppressed CDK2 and CDK4 activities by 80% and 60%, respectively. To examine the dose effect of tranilast on activities of CDK2, CDK4, and cyclin E-and cyclin D1-associated kinases, we measured the kinase activities of their immunoprecipitates at 18 hours after 10% FBS or PDGF stimulation. Treatment of SMCs with 10% FBS or PDGF resulted in an increase of CDK2 activity by 20-or 10-fold, respectively. Tranilast (100 to 300 mol/L) inhibited the kinase activities of both anti-CDK2 and anti-CDK4 immunoprecipitates in a dose-dependent manner (IC 50 value was Ϸ150 mol/L). The cyclin D1-and cyclin E-associated kinase activities were also inhibited by tranilast treatment, although they were less marked than anti-CDK2/anti-CDK4 -immunoprecipitated kinase activities ( Figure 2B) .
To examine the possibility that tranilast could affect CDK and cyclin expression, we tested it by Western blotting ( Figure 2C ). Mitogenic stimulation induced an elevation of cyclin D1 but did not alter the expression of CDK2, CDK4, and cyclin E. Tranilast (100 to 300 mol/L) did not alter the protein levels of CDK2, CDK4, cyclin E, and cyclin D1 in cells exposed to 10% FBS or PDGF.
Effect of Tranilast on the Expression of p21 and p53
Because p21 inhibits the activities of cyclin E/CDK2 and cyclin D1/CDK4 complexes, we investigated the effect of Figure 1 . Effect of tranilast on pRb phosphorylation. Quiescent (serum depleted for 48 hours) SMCs were stimulated with PDGF-BB (10 ng/mL), 2% FBS, and ITS or FBS (10%) for 18 hours. Cell lysates were subjected to immunoprecipitation using anti-pRb antibody. Immunoprecipitates were subjected to immunoblotting with anti-pRb monoclonal antibody after SDS-PAGE on a 7.5% gel. A representative immunoblot is shown. Signals were visualized by the ECL system. C indicates control (medium only); D, DMSO used as a solvent of tranilast and added to medium; and ppRb, phosphorylated form of pRb.
tranilast on p21 expression by PDGF. In control cells, Western blotting showed a considerable amount of p21 protein in quiescent SMCs (serum depleted for 2 days). The expression of p21 increased transiently at 16 hours after PDGF stimulation and decreased at 24 hours. In the presence of tranilast (300 mol/L), there was little decrease in the amount of protein, resulting in continuous and elevated expression throughout the observed period; amount of p21 increased Ͼ4-fold (by densitometric analysis) at 24 hours after PDGF stimulation compared with that of control cells (Figure 3 ). To test whether tranilast induces p21 through the induction of p53, we examined the effect of tranilast on the expression of p53. The level of p53 increased after PDGF stimulation, but this increase was not so marked compared with the increase of p21 by tranilast treatment (Figure 3 ).
Association of p21 With CDK2, CDK4, and Cyclins
To further explore whether the observed inhibition of CDK2 and CDK4 activities were attributable to the association of p21 with CDK2 and CDK4, we immunoprecipitated p21 from the lysates of cells at the indicated times in the presence or absence of tranilast (300 mol/L). Figure 4B reveals that CDK2 was coimmunoprecipitated by anti-p21 antibody, indicating the association of them in vitro. In this experiment, a slightly faster migrating band was detected. This band (faster migrating) was thought to represent CDK2 phosphorylated on threonine residue (Thr160 in CDK2). 29 In control cells, p21/CDK2 complexes decreased at 24 hours after PDGF stimulation. However, in tranilast-treated cells, the complexing of CDK2 with p21 was maintained at high levels; this led to an inactivation of CDK2 activity. The p21/CDK4 complexes were also increased in tranilast-treated cells at 24 hours after PDGF stimulation ( Figure 4C ), suggesting that not only p21/CDK2 but also p21/CDK4 complex is important in tranilast-mediated growth inhibition of SMCs.
Next, we examined the amount of cyclin D1 and E remaining in the supernatant after immunoprecipitating with anti-p21 antibody. We immunoprecipitated p21 from the Cell lysates prepared at indicated times were immunoprecipitated with either anti-CDK2 or CDK4 antibody. After the kinase reaction using histone H 1 (for CDK2) or GST-Rb (for CDK4) as substrate, the assay mixture was fractionated by SDS-PAGE (acrylamide concentration was 12.5% for histone H 1 and 10% for GST-Rb), and relative kinase activities were determined from band intensities on a BAS 2000 bioimager. B, Cell lysates were prepared at 18 hours after 10% FBS or PDGF stimulation in the presence of various concentrations of tranilast (100 to 300 mol/L). Lysates were then immunoprecipitated with anti-CDK2, anti-cyclin E (CycE), anti-CDK4, and anti-cyclin D1 (cycD1) antibodies. The kinase reaction was performed as described in panel A using histone H 1 (for CDK2 and cyclin E) or GST-Rb (for CDK4 and cyclin D1) as substrate. C indicates control (medium only); D, DMSO used as a solvent of tranilast and added into medium. C, Cells were harvested at 18 hours after stimulation, and proteins (70 g) were fractionated by 10% SDS-PAGE. Western blotting was performed with antibodies to CDK2, CDK4, cyclin E, and cyclin D1. Signals were visualized by the ECL system; abbreviations as in panel B. Figure 3 . Effect of tranilast on p21 and p53 expression. Quiescent (serum depleted for 48 hours) SMCs were preincubated with tranilast (300 mol/L) or DMSO for 1 hour (time 0). Cells were then stimulated with PDGF-BB (10 ng/mL), 2% FBS, and ITS. SMCs were harvested at the indicated times, and then lysates were immunoprecipitated with antibody to p53 (Ab-1, Calbiochem) or p21(Santa Cruz Biotechnology). Proteins were resolved by SDS-PAGE and immunoblotted with a polyclonal antibody to p53 (Ab-7, Calbiochem) and a monoclonal antibody to p21 (Upstate Biotechnology). Signals were visualized by the ECL system. C indicates control (medium only).
lysates of cells at 24 hours after 10% FBS stimulation in the presence or absence of tranilast (300 mol/L). Then, supernatant was subjected to immunoblotting with either anticyclin D1 or anti-cyclin E antibody. In tranilast-treated cells, the amount of cyclin D1 in the supernatant was Ϸ50% less compared with the control; however, we found no difference in the cyclin E levels ( Figure 5A ). Furthermore, there was no difference in the amount of p27 with or without tranilast treatment. In case of PDGF stimulation, we found that the amount of cyclin D1 in the supernatant was also decreased, but we found no difference in the amount of cyclin E (data not shown).
To confirm the increased association of p21 with cyclin/ CDK complex, we immunoprecipitated cyclin D1 and cyclin E at 24 hours after 10% FBS stimulation and then examined them with anti-p21 or anti-p27 antibody. As shown in Figure  5B , we found an increased association of p21 with cyclin D1 by 2-fold compared with the control; however, we could not detect p27 alteration in either cyclin D1 or cyclin E immunoprecipitates (data not shown). These data suggest that tranilast induces p21 without affecting p27 expression, and the increased p21 makes more complexes with cyclin D1.
Tranilast Inhibits Neointimal Thickening of the Rat Carotid Artery After Balloon Injury
Our in vitro experiments revealed that tranilast potently inhibited both PDGF-and FBS-induced cell proliferation. To determine whether these effects were applicable in vivo to inhibit neointimal formation after arterial injury, tranilast was administered as a dietary supplement before balloon injury of the carotid artery. Plasma level of tranilast was 289Ϯ25 mol/L when rats were euthanized. Tranilast significantly inhibited the accumulation of neointimal SMCs in injured vessel at 14 days (data not shown). Quantitative analysis of the injured segments of arteries showed that tranilast-fed animals had a 70% less neointima/media area ratio than controls (0.443Ϯ0.071 versus 1.450Ϯ0.138 [nϭ8]
for tranilast-treated and normal chow controls, respectively, PϽ0.001). Tranilast-fed animals exhibited similar weight gain and exhibited no other evidence of toxicity compared with the normal chow-fed rats.
Tranilast Induces p21 Expression in the Neointimal SMCs After Balloon Injury of the Rat Carotid Artery
To determine whether these in vivo effects were associated with changes in p21 expression, we examined the expression of p21 by immunohistochemistry at 2, 7, and 14 days after balloon injury. p21 expression was undetectable in uninjured vessels and Figure 4 . Effect of tranilast on association of p21 with CDK2 and CDK4. Quiescent (serum starved for 48 hours) SMCs were treated with PDGF (10 ng/mL), 2% FBS, and ITS for indicated times in the presence or absence of tranilast (300 mol/L). Equal amounts of cell lysates were subjected to immunoprecipitation with rabbit anti-p21 antibody. Immunoprecipitates were loaded onto 12.5% SDS-polyacrylamide gels. After electrophoresis, samples were transferred to PVDF membrane, followed by Western immunoblot analysis with anti-p21 (A), anti-CDK2 (B), and anti-CDK4 (C) antibody. Signals were visualized by the ECL system. Figure 5 . Effect of tranilast on association of p21 and cyclin D1 and cyclin E. A, Quiescent (serum depleted for 48 hours) SMCs were preincubated with tranilast or DMSO for 1 hour (time 0). Cells were then stimulated with 10% FBS. SMCs were harvested at 24 hours (total cell lysates), and then lysates were immunoprecipitated with polyclonal antibody to p21(Santa Cruz Biotechnology). The supernatants, total cell lysates, and immunoprecipitates were loaded onto 12.5% SDS-polyacrylamide gels. After electrophoresis, the samples were transferred to PVDF membrane, followed by Western immunoblot analysis with anti-p21, anti-cyclin D1, or anti-cyclin E antibody. Immunoprecipitated p21 and total cell lysates were probed using monoclonal anti-p21 (Upstate Biotechnology) or p27 (Santa Cruz Biotechnology) antibody, respectively. Abbreviations as in Figure  2B . B, Quiescent (serum depleted for 48 hours) SMCs were preincubated with tranilast or DMSO for 1 hour (time 0). Cells were then stimulated with 10% FBS. SMCs were harvested at 24 hours, and then lysates were immunoprecipitated with polyclonal antibody to cyclin D1 or cyclin E. Immunoprecipitates were analyzed with anti-cyclin D1, anti-cyclin E, and anti-p21. Signals were visualized by the ECL system. ␣ indicates "anti-"; all other abbreviations as in Figure 2B .
in sections incubated with nonimmune rabbit IgG (data not shown). 30 At 2 days after injury, many medial SMCs in the rat carotid artery died, and p21 was detected mainly in the adventitia lesion ( Figure 6A ). The p21-positive adventitial cells seemed to be reduced in the tranilast-treated group ( Figure 6B ). At day 7 after injury, a proliferative neointimal lesion was starting to form in control rats ( Figure 6C ). In the tranilast-treated group, cells in the neointima were already stained with anti-p21 ( Figure 6D ), whereas p21 was not expressed in the control (Figure 6C ). At day 14 after injury, when a prominent intimal lesion was formed, p21 expression was seen predominantly on the luminal surface of the intima, but it was very low or undetectable in the media ( Figure 6E ) in normal chow-fed rats. As shown in Figure 6F , in tranilast-treated rats, p21 expression was detected throughout the intima lesion and was also noted in the media and adventitia. Taken together, these results indicate that p21 is expressed earlier in tranilast-treated rats and may contribute to inhibition of neointimal formation after balloon injury. Figure 6 . In vivo expression of p21 after balloon injury of rat carotid artery. p21 immunostaining is shown in arteries at days 2 (A and B), 7 (C and D), and 14 (E and F) after balloon injury. At day 2, p21 was detected mainly in the adventitia lesion both in control and tranilast-treated rats (A and B). At day 7, in tranilast-treated rats, p21 was already expressed (D), although it was not in normal controls (C). At day 14, in normal chow-fed rats, p21 was observed predominantly in the luminal surface of the intima, but it was very low or undetectable in the media (E). In tranilast-treated rats, p21 was abundant throughout the intimal lesion; note that it was expressed also in the media and adventitia lesion (F). Magnification ϫ50. A through F, Arterial lumen is on top and adventitia is on bottom. The polyclonal anti-human p21 antibody (No. sc-756, Santa Cruz Biotechnology) was used.
Discussion
In this study, we showed that tranilast has a strong antiproliferative effect on SMCs both in vitro and in vivo without affecting the early signal-transduction pathway by PDGF stimulation. To elucidate this mechanism, we examined the effect of tranilast on pRb, cyclin, and CDK activity. Although tranilast completely inhibited the CDK2 activity ( Figure 2B , rows 7 and 11), a faint phosphorylated pRb band was still observed (Figure 1 ). According to a recent report, pRb has multiple CDK consensus phosphorylation sites, and each of them may have a specific function of regulating the binding of pRb to various proteins, such as E2F, c-Abl, and SV40 large T antigen. 31 This implies that CDK4 and other CDKs phosphorylate the specific sites of pRb distinct from those phosphorylated by CDK2. This may be the reason why pRb was phosphorylated despite complete inhibition of CDK2 activity.
Cyclin levels have been shown to be rate-limiting factors for G 1 progression in mammalian cells, and many studies show that synthesis of cyclins, especially D-type cyclins, may be the target of physiological signals that control cell proliferation. We found that tranilast did not reduce the protein levels of these cyclins and CDKs ( Figure 2C ). Therefore, we conclude that other mechanisms are involved in tranilastinduced inhibition of CDK2 and CDK4 activities. In addition to cyclin binding, complete CDK activation requires phosphorylation at a conserved threonine residue (Thr160 in CDK2). 29 Activation of CDK2 during S phase is accompanied by an increase in its electrophoretic mobility. In our results, tranilast did not affect the mobility shift of CDK2 during S phase (data not shown); therefore CDK-activating kinase was not responsible for the inhibitory effect of tranilast.
p21, wild-type p53-activated fragment 1 (Waf1), 32 CDKinactivating protein 1 (Cip1), and senescent cell-derived inhibitor 1 bind to cyclin-CDK2 complexes. The catalytic activity of each member of the CDK family can be inhibited by p21, although their relative affinities vary with each enzyme. In our results, p21 protein was detectable in quiescent SMCs (Figure 3, control) . In tranilast-treated cells, p21 remains persistently upregulated at high levels and associates with cyclin/CDK2/CDK4 ( Figure 4B and 4C) and inhibits their activities ( Figure 2B ), whereas in control cells, the reduction of p21/CDK2/CDK4 complexes permits cells to traverse the cell cycle and enter S phase. To confirm this, when cyclin D1 was immunoprecipitated, we found an increased association of p21 with cyclin D1. Furthermore, when p21 was immunodepleted, the amount of cyclin D1 remaining in the supernatant was reduced to the same level as in quiescent control cells ( Figure 5A ). Therefore, tranilastinduced p21 makes more complexes with cyclin D1 and inhibits cyclin D1/CDK4 activities. It has been reported that pRb is sequentially phosphorylated by CDK4/cyclin D1 followed by CDK2/cyclin E complexes. 33 Tranilast may inhibit initial CDK4/cyclin D1 activities by complexing with p21 and result in inactivation of subsequent CDK2/cyclin E activities.
The elevated levels of p53 protein at 24 hours after PDGF stimulation were not as marked as those of p21 (Figure 3 ). These data suggest that p21 induction by tranilast depends on p53 in part; however, tranilast inhibited the growth of HL-60, a cell line that lacks wild-type p53 (A. Takahashi, unpublished results, 1998). Therefore, p53 is not a prerequisite for tranilast to inhibit cell proliferation. Other CDK-inactivating proteins, p27 ( Figure 5A ) and p16 (data not shown), were also examined, but neither of them were induced by tranilast treatment.
More recently, it has been reported that CDK2, cyclin E, and cyclin A are induced in balloon-injured rat carotid arteries. Immunohistochemical staining of human restenotic legions also revealed the expression of CDK2, cyclin E, and proliferating cell nuclear antigen in ␣-smooth muscle actinimmunoreactive cells, and p21 expression was followed up to 60 hours after balloon injury. 34 According to that report, p21 is not involved in the maintenance of the postmitotic state of SMC in vivo. On the other hand, it is reported that p21 is induced in porcine arteries after balloon catheter injury to play an important role in limiting arterial cell proliferation in vivo. 30, 35 Moreover, adenovirus-mediated overexpression of p21 inhibits vascular SMC proliferation and neointima formation in the rat carotid artery model of balloon angioplasty, 36 which suggests that p21 functions to block cell cycle progression and to promote growth arrest in vascular cells in vivo. The demonstration that tranilast inhibits the development of neointima shows its potential utility to inhibit human restenosis by upregulating p21 expression. Plasma levels of tranilast in the rat, 3 days after administration, were 250 to 300 mol/L. These plasma levels seem to be compatible with the concentrations of tranilast used in the vitro study, which inhibited SMC proliferation.
The initial response to injury in the rat model is reported to be SMC proliferation in the media. 28 Within 24 hours after balloon catheter injury, medial SMCs start to replicate, and by day 4, these cells migrate into the intima. Medial SMC replication reaches a peak between 2 and 3 days after injury, is reduced by 7 days, and is undetectable at 14 days. In this study, at 2 days after injury, balloon catheterization caused cell injury or death in the media, and p21 immunoreactivity was detected mainly in the adventitia ( Figure 6A and 6B) . Presently, we cannot explain why adventitial cells were positive for p21 in both the control and the tranilast-treated group. In addition, p21 immunoreactivity was not observed in the media by day 7; therefore, it seems too late for p21 to inhibit the replication of medial SMC. However, little is known as to why this medial proliferation is so important. Further studies are needed to evaluate the significance of medial and adventitial p21 expression.
If SMC replication in an injured artery is examined at a variety of times, the highest rates of replication are found in the intima, not in the media. This intimal replication, unlike that of the media, is sustained for several weeks. 37 At 7 days after injury, p21 was already expressed in the neointima of carotid artery in tranilast-treated rats, but was not in normal chow-fed rats. These data suggest that tranilast inhibits intimal cell proliferation by expressing p21 and diminished the size of the final intimal area. Further studies that aim to elucidate mechanisms underlying the upregulation of p21 in the adventitial, medial, and intimal SMCs should not only provide insight into the pathophysiology of restenosis but may also have important implications for developing approaches to prevent restenosis after angioplasty.
Our findings demonstrate that inhibition of CDK2/CDK4 activities by the increased expression of p21 is one mechanism by which tranilast inhibits SMC proliferation and prevents postangioplasty restenosis.
